Industry Spotlight Session 19

29 Mar 2026 2:30 p.m. 3 p.m.
Spotlight Stage 2
DavidCherney Chair Canada
Session Title : Treating CV risk in CKD: from identification to intervention

Organized By: Boehringer Ingelheim

Session Description : This will be an engaging interview-style presentation and discussion between a nephrologist and cardiologist focused on a non-diabetic patient case with CKD including audience interaction. The discussion will emphasise the importance of assessing CV risk in people with CKD, drawing on the expertise of the cardiologist and their knowledge of CV risk calculators. The session will highlight the urgency of addressing CV risk in people with CKD alongside their kidney disease.

Learning Objectives:

1. Emphasise the urgency to identify and manage elevated CV risk in patients with CKD
2. Examine the wealth of evidence and international guideline support for the use of SGLT2 inhibitors in patients with CKD for both kidney and CV benefits
3. Empower nephrologists to use CV risk assessment tools, including risk calculators, in their clinic through educational discussions with a cardiologist

 

Time Session
2:30 p.m.
2:33 p.m.
Welcome and introduction
DavidCherney Chair david.cherney@uhn.on.caCanada
2:33 p.m.
2:39 p.m.
More than CKD: identifying and managing CV risk in patients With CKD
DavidCherney Speaker david.cherney@uhn.on.caCanada
2:39 p.m.
2:45 p.m.
Audience Q&A
DavidCherney Moderator david.cherney@uhn.on.caCanada
Toshiyuki Ko Moderator tkou-tky@umin.ac.jpJapan
2:45 p.m.
2:51 p.m.
From the kidneys to the heart: practical management tools for CV risk in patients with CKD
Toshiyuki Ko Speaker tkou-tky@umin.ac.jpJapan
2:51 p.m.
2:57 p.m.
Audience Q&A
DavidCherney Moderator david.cherney@uhn.on.caCanada
Toshiyuki Ko Moderator tkou-tky@umin.ac.jpJapan
2:57 p.m.
3 p.m.
Summary and close
DavidCherney Chair david.cherney@uhn.on.caCanada